Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
At week 108, 43.8% of patients had a ≥20% decrease in FSS score, and 31.2% of patients had a ≥30% decrease in FSS score. In patients with baseline depressive symptoms, a significant improvement ...